RANI Logo

Rani Therapeutics Holdings, Inc. (RANI) 

NASDAQ
Market Cap
$140.73M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
34 of 776
Rank in Industry
29 of 433

Largest Insider Buys in Sector

RANI Stock Price History Chart

RANI Stock Performance

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical …

Insider Activity of Rani Therapeutics Holdings, Inc.

Over the last 12 months, insiders at Rani Therapeutics Holdings, Inc. have bought $10.77M and sold $20.72M worth of Rani Therapeutics Holdings, Inc. stock.

On average, over the past 5 years, insiders at Rani Therapeutics Holdings, Inc. have bought $38.9M and sold $10.79M worth of stock each year.

Highest buying activity among insiders over the last 12 months: South Cone Investments Limited Partnership (10 percent owner) — $21.17M. BUTEL JEAN LUC (director) — $102,495. Imran Talat (Chief Executive Officer) — $86,525.

The last purchase of 10,000 shares for transaction amount of $22,700 was made by Imran Talat (Chief Executive Officer) on 2023‑12‑06.

List of Insider Buy and Sell Transactions, Rani Therapeutics Holdings, Inc.

2024-10-15Sale10 percent owner
3.83M
8.9999%
$2.65$10.14M+13.68%
2023-12-06PurchaseChief Executive Officer
10,000
0.0173%
$2.27$22,700+31.52%
2023-12-04PurchaseChief Executive Officer
5,000
0.0101%
$2.57$12,850+36.16%
2023-11-29PurchaseChief Executive Officer
20,000
0.0409%
$2.05$41,000+72.56%
2023-11-24Sale10 percent owner
5.27M
10.2552%
$2.01$10.58M+67.01%
2023-11-24Purchase10 percent owner
5.27M
10.2552%
$2.01$10.58M+67.01%
2023-11-17Purchasedirector
50,500
0.0962%
$2.03$102,495+65.92%
2023-11-16Purchasedirector
500
0.0009%
$1.98$990+66.50%
2023-11-07PurchaseChief Executive Officer
5,000
0.0095%
$2.00$9,975+67.42%
2023-05-12Purchase10 percent owner
2,645
0.0104%
$3.98$10,529-10.45%
2023-05-11Purchase10 percent owner
2,610
0.0102%
$3.87$10,096-8.04%
2023-05-08Purchase10 percent owner
4,420
0.0183%
$4.46$19,733-15.65%
2023-05-03Purchase10 percent owner
2,040
0.0082%
$4.81$9,816-23.68%
2023-04-28Purchase10 percent owner
2,173
0.0086%
$4.71$10,225-23.40%
2023-04-25Purchase10 percent owner
4,423
0.0172%
$4.51$19,952-21.35%
2023-04-24Purchase10 percent owner
4,280
0.0169%
$4.67$19,994-23.19%
2023-04-21Purchase10 percent owner
4,100
0.0166%
$4.93$20,224-25.47%
2023-04-20Purchase10 percent owner
1,850
0.0074%
$5.32$9,851-31.72%
2023-04-18Purchase10 percent owner
1,850
0.0074%
$5.37$9,939-32.40%
2023-04-14Purchase10 percent owner
1,901
0.0076%
$5.27$10,019-31.30%

Insider Historical Profitability

<0.0001%
South Cone Investments Limited Partnership10 percent owner
8302194
14.7186%
$2.50641<0.0001%
Imran TalatChief Executive Officer
484455
0.8589%
$2.5040
BUTEL JEAN LUCdirector
50500
0.0895%
$2.5010
Quiroga Cortes Isidoro Alfonso10 percent owner
8400
0.0149%
$2.5051<0.0001%
Nanavaty Maulikdirector
500
0.0009%
$2.5010

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$2.13M1.36685,303+2.54%+$52,733.15<0.0001
Nan Fung Group$1.54M0.98493,5840%+$01.67
USAA$1.5M0.96481,3000%+$00.04
Alphabet$1.39M0.89448,4920%+$00.01
Stifel$411,866.000.26132,434+163.47%+$255,540.16<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.